Director share purchases. 08/01/08

Guildford, UK, 7 January 2008: ReNeuron Group plc (LSE: RENE.L) was advised today of the following purchases of Ordinary shares in the Company by directors of the Company:-

Director	Number of shares purchased and price per share	Total shareholding after purchase
Professor Trevor Jones (Chairman)	28,000 at 17.8p	111,200
Michael Hunt (Chief Executive Officer)	33,000 at 18.38p	237,113
Dr John Sinden (Chief Scientific Officer)	28,328 at 17.65p	1,395,913
Mark Docherty (Non-executive Director	28,000 at 17.8p	174,400
Dr Paul Harper (Non-executive Director)	27,600 at 18.025p	110,800

Notes to editors

ReNeuron is a leading, UK-based stem cell therapy business. It is applying its novel stem cell platform technologies in the development of ground-breaking stem cell therapies to serve significant and unmet or poorly-met clinical needs. The Company operates from laboratories in Surrey, UK and Los Angeles, California, USA.

ReNeuron has used its c-mycER technology to generate genetically stable neural stem cell lines. This technology platform has multi-nationa patent protection and is fully regulated by means of a chemically-induced safety switch. Cell growth can therefore be completely arrested prior to in vivo implantation.

ReNeuron has filed for approval to commence initial clinical studies in the US with its lead ReN001 stem cell therapy for chronic stroke disability. There are an estimated 50 millionstroke survivors worldwide, approximately one half of which are left with permanent disabilities. The annual health and social costs of caring for these patients is estimated to be in excess of £5 billion in the UK and in excess of US$50 billion in the US.

In addition to its stroke programme, ReNeuron is developing stem cell therapies for Parkinson's disease, Huntington's disease, Type 1 diabetes and diseases of the retina. The Company recently announced the acquisition of the business assets of AmCyte Inc. in the US, bringing clinically-tested cell encapsulation technology to ReNeuron's ReN002 diabetes programme.

ReNeuron has leveraged its stem cell technologies into non-therapeutic areas – its ReNcell^®range of cell lines for use in research and in drug discovery applications in the pharmaceutical industry. ReNeuron's ReNcell^®CX and ReNcell^®VM neural cell lines are marketed worldwide under license by Millipore Corporation.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.

Further information on ReNeuron and its products can be found at www.reneuron.com.

Data sources: UK Stroke Association; American Stroke Association.

Further information

ReNeuron
Michael Hunt, Chief Executive Officer
Tel: +44 (0) 1483
302560

Financial Dynamics
Europe
David Yates
Tel:
+44 (0) 20 7831 3113
Lara Mott

US
Robert Stanislaro
Tel :
+1 212 850 5657

This announcement contains forward-looking statements with respect to the financial condition, results of operations and business achievements/performance of ReNeuron and certain of the plans and objectives of management of ReNeuron with respect thereto. These statements may generally, but not always, be identified by the use of words such as "should", "expects", "estimates", "believes" or similar expressions. This announcement also contains forward-looking statements attributed to certain third parties relating to their estimates regarding the growth of markets and demand for products. By their nature, forward-looking statements involve risk and uncertainty because they reflect ReNeuron's current expectations and assumptions as to future events and circumstances that may not prove accurate. A number of factors could cause ReNeuron's actual financial condition, results of operations and business achievements/performance to differ materially from the estimates made or implied in such forward-looking statements and, accordingly, reliance should not be placed on such statements

Top of page

Back to News